Hemodialysis

Outset Medical to Present at BofA Securities 2021 Virtual Health Care Conference

Retrieved on: 
Tuesday, April 27, 2021

b'Outset Medical, Inc. (Nasdaq: OM) (\xe2\x80\x9cOutset\xe2\x80\x9d), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 11:45am PT / 2:45pm ET.\nOutset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.

Key Points: 
  • b'Outset Medical, Inc. (Nasdaq: OM) (\xe2\x80\x9cOutset\xe2\x80\x9d), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 11:45am PT / 2:45pm ET.\nOutset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis.
  • The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers.
  • Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone.
  • Tablo is a registered trademark of Outset Medical, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210427006034/en/\n'

Dialysis Market Revenue to Cross USD 114 Bn by 2027: Global Market Insights Inc.

Retrieved on: 
Tuesday, April 27, 2021

b'SELBYVILLE, Del., April 27, 2021 /PRNewswire/ --According to the latest report "Dialysis Market by Type (Hemodialysis, Peritoneal Dialysis), Product & Service (Equipment, Consumables, Services), End-use (In-center Dialysis, Home Dialysis), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights Inc., the market valuation of dialysis will cross $114 billion by 2027.

Key Points: 
  • b'SELBYVILLE, Del., April 27, 2021 /PRNewswire/ --According to the latest report "Dialysis Market by Type (Hemodialysis, Peritoneal Dialysis), Product & Service (Equipment, Consumables, Services), End-use (In-center Dialysis, Home Dialysis), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights Inc., the market valuation of dialysis will cross $114 billion by 2027.
  • Similarly, availability of efficient dialysis services in dialysis centers and home settings has led to an increased demand for such services among the patient population for effective patient care.\nHome dialysis segment in the dialysis market accounted for more than USD 24 billion in 2020.
  • Additionally, home dialysis offers numerous benefits including flexible schedule, and patient mobility that further secures the segment growth.\nAsia Pacific dialysis market captured over 27% of revenue share in 2020.
  • These market leaders are focusing on developing innovative products that helps the company increase its revenue share internationally.\nTable of Contents (ToC) of the report:\n'

Global $127.4 Billion Dialysis Market Insights & Forecasts to 2024 Featuring Fresenius Medical Care, DaVita, Baxter International, B.Braun, Asahi Kasei, & Nipro

Retrieved on: 
Monday, April 12, 2021

b'DUBLIN, April 12, 2021 /PRNewswire/ -- The "Global Dialysis Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global dialysis market is estimated to reach US$127.4 billion in 2024, growing at a CAGR of 6.29% for the period spanning from 2020 to 2024.\nThe factors such as higher prevalence among aging population, increasing diabetic population, rising healthcare spending and increasing cases of ESRD are expected to drive the market.\nHowever, growth of the industry will be challenged by high treatment costs, stringent regulations and rising kidney transplantation procedures.

Key Points: 
  • b'DUBLIN, April 12, 2021 /PRNewswire/ -- The "Global Dialysis Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com\'s offering.\nThe global dialysis market is estimated to reach US$127.4 billion in 2024, growing at a CAGR of 6.29% for the period spanning from 2020 to 2024.\nThe factors such as higher prevalence among aging population, increasing diabetic population, rising healthcare spending and increasing cases of ESRD are expected to drive the market.\nHowever, growth of the industry will be challenged by high treatment costs, stringent regulations and rising kidney transplantation procedures.
  • A few notable trends include rising demand for home dialysis, favorable reimbursement structure, technological advancements and preference of dialysis treatment over the transplant.\nThe global dialysis market is segmented into hemodialysis and peritoneal dialysis.
  • The global dialysis market is highly dominated by hemodialysis owing to a preference for dialysis treatment over transplant, rising prevalence of kidney diseases and a rising number of dialysis centers.\nThe global dialysis market is expected to grow in future due to the growing number of patients suffering from diabetes, increasing healthcare expenditure and rising awareness regarding kidney diseases.
  • In terms of geographical areas, North America and Europe are major contributors to the global dialysis market supported by growing cases of end-stage renal diseases and surge in funding for the development of new products with advanced technology.\nThe report provides a comprehensive analysis of the global dialysis market, segmented into hemodialysis and peritoneal dialysis.\nThe major regional markets (North America, EMEA and the Asia Pacific) have been analyzed.\nThe market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.\nThe competitive landscape of the market, along with the company profiles of leading players (Fresenius Medical Care AG & Co. KGaA, DaVita Inc., Baxter International Inc., B.Braun , Asahi Kasei Corporation, Nipro Corporation) are also presented in detail.\n'

Outset Medical Named a Winner in Round 2 of the KidneyX COVID-19 Kidney Care Challenge

Retrieved on: 
Friday, April 9, 2021

The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have named Outset Medicals Tablo Hemodialysis System one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge , recognizing innovative solutions for safely delivering kidney care during the pandemic.

Key Points: 
  • The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have named Outset Medicals Tablo Hemodialysis System one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge , recognizing innovative solutions for safely delivering kidney care during the pandemic.
  • The KidneyX COVID-19 Kidney Care Challenge recognizes solutions that reduce the transmission of the coronavirus among people with kidney diseases and/or reduce the risk of kidney damage among people who contract the virus.
  • With a total prize pool of $300,000, the KidneyX COVID-19 Kidney Care Challenge aims to share processes, systems, best practices and tools with frontline communities.
  • KidneyX seeks to improve the lives of people with kidney disease by expediting the development of drugs, devices, biologics, and other therapies across the spectrum of kidney care.

Spectral Medical’s Dialco Medical Announces 20 Year Exclusive License Agreement for DIMI Hemodialysis System in the United States and Canada

Retrieved on: 
Thursday, April 8, 2021

TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (Dialco) has entered into an expanded, long-term licensing agreement with Infomed SA (Infomed) for the DIMI hemodialysis system, extending Dialcos exclusive rights in the United States and Canada through 2041.

Key Points: 
  • TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (Dialco) has entered into an expanded, long-term licensing agreement with Infomed SA (Infomed) for the DIMI hemodialysis system, extending Dialcos exclusive rights in the United States and Canada through 2041.
  • Dialco recently received 510(k) clearance by the United States Food & Drug Administration (FDA) for DIMI for use within a wide variety of settings including hospitals, clinics, and skilled nursing facilities.
  • In March 2021, Dialco obtained its DIMI Health Canada license for use in Canadian hospitals, clinics and in home.
  • There remains one final Health Canada license for DIMI to unlock the full dialysis modality of the device.

Global Dialysis Market Insights & Forecasts Report 2020-2024 - Rising Demand for Home Dialysis / Favorable Reimbursement Structure / Technological Advancements - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 8, 2021

The "Global Dialysis Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dialysis Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • A few notable trends include rising demand for home dialysis, favorable reimbursement structure, technological advancements and preference of dialysis treatment over the transplant.
  • The global dialysis market is highly dominated by hemodialysis owing to a preference for dialysis treatment over transplant, rising prevalence of kidney diseases and a rising number of dialysis centers.
  • The report provides a comprehensive analysis of the global dialysis market, segmented into hemodialysis and peritoneal dialysis.

Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine

Retrieved on: 
Friday, March 12, 2021

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments.
  • The AK 98 dialysis machine is indicated to be used on patients with a body weight of 25kg or more.
  • This release includes forward-looking statements concerning the AK 98 dialysis machine and Theranova, including anticipated availability and potential benefits associated with their use.
  • Baxter, AK 98 and Theranova are registered trademarks of Baxter International Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005084/en/

Dialyze Direct Expands SNF Home Dialysis Program to Kentucky

Retrieved on: 
Monday, March 8, 2021

"Over the past few months, we have had the privilege of working closely with the Kentucky Department of Health by participating in their pilot program for SNF home hemodialysis," said Josh Rothenberg, Dialyze Direct's Chief Operating Officer.

Key Points: 
  • "Over the past few months, we have had the privilege of working closely with the Kentucky Department of Health by participating in their pilot program for SNF home hemodialysis," said Josh Rothenberg, Dialyze Direct's Chief Operating Officer.
  • Dialyze Direct provides comprehensive, turn-key home dialysis solutions that allow patients with end-stage renal disease (ESRD) to take advantage of the latest in patient-centric dialysis care.
  • Kentuckymarks the eleventh state in which Dialyze Direct is active, with expansion slated for several additional states within the next year.
  • Dialyze Direct has operations inFlorida,Illinois,Indiana,Kentucky, Maryland,New Jersey,New York,Ohio,Pennsylvania,Tennessee, and Texas and is in the process of launching operations in additional states.

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Retrieved on: 
Monday, March 8, 2021

We are delighted that the FDA accepted and granted Priority Review for this breakthrough therapy.

Key Points: 
  • We are delighted that the FDA accepted and granted Priority Review for this breakthrough therapy.
  • Pruritus in hemodialysis patients is a debilitating condition with a significant impact on quality of life and increased risk for hospitalization and mortality.
  • We are highly committed to bringing this important new treatment to patients in the US as soon as possible following FDA approval, together with our partner Cara Therapeutics, commented Stefan Schulze, CEO of Vifor Pharma Group.
  • The FDA acceptance for filing and granting of Priority Review for the KORSUVA NDA marks a significant milestone for Cara and for the substantial number of hemodialysis patients with chronic intractable pruritus, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.

Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Retrieved on: 
Monday, March 8, 2021

The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.

Key Points: 
  • The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.
  • The FDA acceptance for filing and granting of Priority Review for the KORSUVA NDA marks a significant milestone for Cara and for the substantial number of hemodialysis patients with chronic intractable pruritus, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
  • We are delighted that the FDA accepted and granted Priority Review for this breakthrough therapy.
  • Pruritus in hemodialysis patients is a debilitating condition with a significant impact on quality of life and increased risk for hospitalization and mortality.